Skip to main content

CORRECTION article

Front. Immunol., 24 November 2022
Sec. Alloimmunity and Transplantation

Corrigendum: Lymphatic reconstruction in kidney allograft aggravates chronic rejection by promoting alloantigen presentation

Jinwen LinJinwen Lin1Ying ChenYing Chen1Huijuan ZhuHuijuan Zhu2Kai ChengKai Cheng3Huiping WangHuiping Wang1Xianping YuXianping Yu1Mengmeng TangMengmeng Tang2Jianghua Chen*Jianghua Chen1*
  • 1Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
  • 2Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
  • 3Xiangya School of Medicine, Central South University, Changsha, China

A corrigendum on
Lymphatic reconstruction in kidney allograft aggravates chronic rejection by promoting alloantigen presentation

by Lin J, Chen Y, Zhu H, Cheng K, Wang H, Yu X, Tang M and Chen J (2021). Front. Immunol. 12:796260. doi: 10.3389/fimmu.2021.796260

In the published article, there was an error in Figure 1D as published. To reveal the expression of VEGF-D at week 4 in the allograft group, it had been accidentally replaced by the acquired image of the allograft group at week 8 when we used AI software to typeset for manuscript preparation. The corrected Figure 1 and its caption are shown as below:

FIGURE 1
www.frontiersin.org

Figure 1 Chronic rejection is associated with lymphangiogenesis in renal allograft. (A) Representative immunofluorescence images of LYVE-1, CD31, and DAPI within sham (n=6 mice), isograft (n=6 mice) and allograft (n=6 mice) kidneys at 1, 4 and 8 weeks respectively. (B, C) Numbers and area counting of LYVE-1+ vessels in high-power field (HPF) at 1, 4 and 8 weeks respectively. (D) Immunohistochemistry of VEGF-C, VEGF-D and FGF-2 expression within sham, isograft and allograft kidneys at 1, 4 and 8 weeks respectively. (E) Positive ratio of VEGF-C, VEGF-D and FGF-2 within sham, isograft and allograft kidneys at 1, 4 and 8 weeks respectively. (F) Relative mRNA expression of VEGF-C, VEGF-D and FGF-2 by qRT-PCR within isograft and allograft kidneys at 1, 4 and 8 weeks respectively, using sham as a reference. (G) Live single CD45- PDPN+ CD31+ LECs isolating from renal allograft by gating technology via flow cytometry, and the population of Ki67+ cells. (H) The ratio of Ki67+ cells in PDPN+CD31+ LECs within sham, isograft and allograft kidneys at 1, 4 and 8 weeks respectively. *P < 0.05, **P < 0.01, ***P < 0.001. Values are mean ± SEM.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: transplantation, chronic rejection, inflammation, lymphangiogenesis, allograft

Citation: Lin J, Chen Y, Zhu H, Cheng K, Wang H, Yu X, Tang M and Chen J (2022) Corrigendum: Lymphatic reconstruction in kidney allograft aggravates chronic rejection by promoting alloantigen presentation. Front. Immunol. 13:1071763. doi: 10.3389/fimmu.2022.1071763

Received: 16 October 2022; Accepted: 11 November 2022;
Published: 24 November 2022.

Edited and Reviewed by:

Zhenhua Dai, Guangdong Provincial Academy of Chinese Medical Sciences, China

Copyright © 2022 Lin, Chen, Zhu, Cheng, Wang, Yu, Tang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jianghua Chen, chenjianghuadoctor@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.